abstract
- Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.
Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- January 2021
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Aged (MeSH)
- Amputation, Surgical (MeSH)
- Canagliflozin (MeSH)
- Cardiovascular Diseases (MeSH)
- Cohort Studies (MeSH)
- Diabetes Mellitus, Type 2 (MeSH)
- Glucagon-Like Peptide 1 (MeSH)
- Heart Disease Risk Factors (MeSH)
- Humans (MeSH)
- Hypoglycemic Agents (MeSH)
- Retrospective Studies (MeSH)
- Risk Factors (MeSH)
published in
- ACP journal club Journal